• purification and concentration anti-FZD7 antibody for the treatment breast cancer
  • houra dinvari,1 Leila Farahmand,2,*
    1. Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
    2. Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran


  • Introduction: Several factors and biomarkers are been used in diagnosis and treatment of breast cancer. Signaling pathways are suitable targets for the development of cancer treatments. One of signaling pathway is Wnt, Secreted Wnt ligands play a major role in the development and progression of many cancers by modulating signaling through cell-surface Frizzled receptors (FZDs). Ten FZDs are encoded in mammalian genomes, and among these, FZD7 has been highlighted in recent years because of its particular contributions to tumor development. FZD7 plays an essential role in carcinogenesis by regulating tumor proliferation and metastasis, maintenance of cancer stem cells, and chemo resistance. The aim of the present research is to purify the anti-FZD7 antibody produced by the clone so that it can be used to treat breast cancer by targeting the FZD7 receptors and it leads to increasing patients survival.
  • Methods: In previous research at the Motamed Breast Research Institute, an anti-FZD7 antibody has been designed and produced. The antibody produced from the mentioned clones has been purified in the present research. The purification method of antibodies included the process of multiple chromatography techniques. Then Due to the presence of His-Tag fusion proteins, in designing the gene sequence for cloning, the desired protein was purified using NTA-Ni affinity chromatography columns. The column outputs were electrophoresed to check the presence of the target protein by SDS PAGE method. After staining the SDS gel and identifying the band, and Amidon column was used to concentrate the desired antibody.
  • Results: The bands related to anti-FZD7 antibody were extracted and purified in SDS PAGE gel with a molecular weight of 22 kD as a single band.
  • Conclusion: The dysregulation of Wnt-β-catenin signaling in cancer and other diseases has generated strong interest in developing therapeutic inhibitors of this pathway. This study has tried to purify and concentrate the designed anti-FZD7 antibody from the produced clones. It is suggested that this antibody be tested on breast cancer cell lines to investigate its effect on the expression of other proteins of the target signaling pathway, including estrogen receptor (ER) and progesterone receptor (PR)
  • Keywords: anti-FZD7 antibody, purification, concentration, breast cancer